Viartril-S/Viartril-S 500 Special Precautions

In asthmatic patients the product should be used with caution as these patients could be more susceptible to develop an allergic reaction to glucosamine with a possible exacerbation of their symptoms.
The sodium content of oral formulations (151 mg for the 1500 mg daily dose) should be taken into consideration by patients on a controlled sodium diet.
No special studies were performed in patients with renal or hepatic insufficiency. The toxicological and pharmacokinetic profile of the product does not indicate limitations for these patients. However, administration to patients with severe hepatic or renal insufficiency should be under medical supervision.
Caution is advised in treatment of patients with impaired glucose tolerance. Closer monitoring of blood sugar levels may be necessary in diabetics at the beginning of treatment.
Glucosamine should not be used in children and adolescents under the age of 18 since safety and efficacy have not been established.
The presence of other joint disease which would require alternative treatment should be excluded.
Note: Glucosamine Sulfate (VIARTRIL-S) is a causal therapy and the therapeutic effect can only be seen after approximately 1 week from the beginning. Therefore, in case of intense pains it is advisable to take an anti-inflammatory drug in addition during the first days of treatment with Glucosamine Sulfate (VIARTRIL-S).
Effects on Ability to Drive and Use Machines: No studies on the effects on the ability to drive and use machines have been performed. No important effects on the CNS or motor system are known that might impair the ability to drive or use machines. However, caution is recommended if headache, somnolence tiredness, dizziness or visual disturbances are experienced.